HHS Halts $500 in Million Vaccine Contracts, Impacting mRNA Research

The U.S. Department of Health and Human Services (HHS) has canceled nearly $500 million in contracts related to vaccine projects, including significant collaborations with Emory University and Tiba Biotech, and rejected proposals from major pharmaceutical companies like Pfizer and Sanofi Pasteur. This decision reflects a notable shift in federal priorities regarding vaccine development, particularly the mRNA technology that was vital during the COVID-19 pandemic. Former BARDA director Rick Bright criticized the cancellations as a strategic error, warning that decreased investment in mRNA platforms could compromise national preparedness for future epidemics. While some near-completion contracts will proceed to protect prior investments, the broader implications for innovation in vaccine technology remain concerning for healthcare professionals.

Opens on Politico